Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The National Cancer Research Institute (NCRI) has announced that Professor Tim Maughan, Emeritus Professor of Clinical Oncology, has been appointed their new Interim CEO.

Tim has worked closely with the NCRI since its establishment in 2001; He was the founding chair of the NCRI Clinical and Translational Radiotherapy Research Working Group, which launched in 2009 to focus on clinical and translational issues relating to radiotherapy. 

Commenting on the news, Tim said:

"I am delighted to be joining the NCRI team. Having worked with NCRI throughout its 20 year history, I am convinced of the importance of its convening role in the cancer research ecosystem. The research groups are key engines for the development of a coordinated, prioritised and innovative clinical cancer research programme in the UK. With our integrated consumer involvement and early career researcher engagement, I look forward to pushing forward the national cancer innovation agenda working closely with our partners."

NCRI Chair Fiona Driscoll commented:

"I am very pleased to announce Professor Tim Maughan as our interim CEO. He has played a significant role in NCRI’s success to date, including setting up CTRad and Chairing our Strategic Advisory Group. It’s a pleasure to welcome him to the team as we launch our new strategy connecting our partners, government and supporters to catalyse the future of cancer research."

Read more about Tim on the Department of Oncology website.